A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.
Also called NCT04218734
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 214 participants
- Registry
-
NCT04218734
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04218734. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-14 (actual); primary completion 2021-06-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- DBPR108
- Intervention (Drug)
- metformin hydrochloride
- Intervention (Drug)
- placepo
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct04218734- Content hash
87ebb15f00fb20ec2ad9226d91750d6ac7e014390311d1d596b15a16c8897833